NCT06255665View on ClinicalTrials.gov

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2025

Conditions
Advanced Stage Solid Tumors
Interventions
DRUG

JNJ-79032421

JNJ-79032421 will be administered.

DRUG

JNJ-79032421

JNJ-79032421 will be administered at RP2D regimen.

Trial Locations (3)

28040

Hosp Univ Fund Jimenez Diaz, Madrid

28050

Hosp Univ Hm Sanchinarro, Madrid

08035

Hosp Univ Vall D Hebron, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT06255665 - A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Biotech Hunter | Biotech Hunter